Aytu reports first full launch quarter for EXXUA, fiscal 2026 results

Aytu BioPharma reported fiscal 2026 fourth-quarter and full-year results on September 22, 2026. EXXUA generated $6.6 million in net revenue during fiscal 2026. The drug became commercially available in mid-December 2025 and reached a more formal launch in mid-January 2026 once sales force training was completed, with full sales force deployment following in late February.¹

EXXUA's fourth-quarter net revenue was $3.9 million, marking the first full quarter of launch.¹ Total prescriptions exceeded 3,300, more than double the prior quarter, and monthly prescriptions hit a record 1,261 in June, with shipments rising nearly 40% sequentially to about 4,600 units.¹ CEO Josh Disbrow said adoption is broadening across prescribers, territories and geographies rather than concentrated among a few, with good conversion from titration packs to full prescriptions, growing refill activity, and favorable early reimbursement dynamics following the launch of national speaker programs.¹

Legacy portfolios continued to shrink. The ADHD Portfolio's fiscal 2026 net revenue fell to $45.8 million from $57.6 million, which the company attributed mainly to its commercial prioritization of EXXUA and generic competition.¹ Pediatric Portfolio revenue dropped to $5.1 million from $8.8 million, also linked to the EXXUA prioritization and reduced promotion.¹

Cash and cash equivalents stood at $26.3 million as of June 30, 2026.¹ On March 31, 2026, the company amended and restated certain warrants, resolving an accounting issue that had required liability classification; this cut derivative warrant liabilities by $26.4 million and raised stockholders' equity by the same amount, leaving derivative warrant liabilities at $1.2 million and stockholders' equity at $35.3 million as of June 30, 2026.¹

Looking ahead, Disbrow said the company aims to build toward more consistent positive Adjusted EBITDA levels as fiscal 2027 progresses.¹